Skip to main content
SpringerLink
Log in

Invasive Urothelial Carcinoma with Molecular Types

  • Chapter
  • First Online:
Urinary Bladder Pathology

  • 759 Accesses

Abstract

Invasive urothelial carcinoma (UC) is a highly aggressive disease characterized by rapid progression and metastasis, requiring significantly different treatment from that of noninvasive UC. Bladder UC invasion is initiated by infiltrative growth through the urothelial basement membrane into the lamina propria (LP). Invasive UC demonstrates a constellation of characteristic morphologic features, which help the recognition of minimal, superficial invasion into the LP in small transurethral biopsy specimens. Cancer invasion also induces fibrosis, inflammation, reaction artifact, and myxoid changes in the adjacent stroma. The muscularis propria (MP) is the major landmark in bladder cancer stage, which divides invasive UC into superficially and deeply invasive diseases; however, MP invasion should be differentiated from muscularis mucosae invasion because of their significant difference in cancer stage and treatment. Lymphovascular invasion is another significant prognostic factor in bladder cancer, but its diagnosis should be strictly based on a set of histologic criteria because of its therapeutic implication. Involvement of the prostate by UC may arise from the bladder or prostatic urethra, which should be staged differently according to cancer origin. Recent genomic studies of invasive bladder UC have revealed several distinct molecular subtypes, which demonstrate not only specific molecular signatures but also different clinicopathologic features. Accurate pathologic and molecular analyses of invasive bladder UC provide crucial guidance in the treatment and prognosis of this aggressive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer. Lancet. 2016;388(10061):2796–810.

    Article  PubMed  Google Scholar 

  2. Grignon DJ, Al-Ahmadie H, Algaba F, Amin MB, Comperat E, Dyrskjot L, Epstein JI, Hansel DE, Knochel R, Lloreta J, Lopez-Beltran A, McKenney JK, Netto GJ, Paner G, Reuter VE, Shen SS, Van der Kwast T. Tumors of the urinary tract. In: Moch H, Humphrey PA, Ulbright TM, Retuer VE, editors. WHO Classification of Tumours of the Urinary System and Male organs. 4th ed (pp.77–135). Lyon: IARC Press; 2016.

    Google Scholar 

  3. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.

    Article  PubMed  Google Scholar 

  4. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196(4):1021–9.

    Article  PubMed  Google Scholar 

  5. Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019;37(1):61–83.

    Article  CAS  PubMed  Google Scholar 

  6. Lobo N, Mount C, Omar K, Nair R, Thurairaja R, Khan MS. Landmarks in the treatment of muscle-invasive bladder cancer. Nat Rev Urol. 2017;14(9):565–74.

    Article  CAS  PubMed  Google Scholar 

  7. Bochner BH, Hansel D, Efstathiou JA, Konety B, Lee CT, McKiernan JM, Plimack ER, Reuter VE, Srdhar S, Vikram R, Stadler WM. Urinary bladder. In: Amin MB, editor. AJCC Cancer Staging Manual, 8th ed (pp.757–765). New York: Springer; 2017.

    Google Scholar 

  8. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56.e25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.

    Article  CAS  Google Scholar 

  12. Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22(Suppl 2):S96–S118.

    Article  PubMed  Google Scholar 

  13. Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019;74(1):77–96.

    Article  PubMed  Google Scholar 

  14. Denzinger S, Burger M, Fritsche HM, Bertz S, Hofstädter F, Wieland WF, et al. Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder. Scand J Urol Nephrol. 2009;43(4):282–7.

    Article  PubMed  Google Scholar 

  15. Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood DP Jr, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol. 2000;24(7):980–7.

    Article  CAS  PubMed  Google Scholar 

  16. Jimenez-Marin A, Collado-Romero M, Ramirez-Boo M, Arce C, Garrido JJ. Biological pathway analysis by ArrayUnlock and Ingenuity Pathway Analysis. BMC Proc. 2009;3(Suppl 4):S6.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Nishiyama N, Kitamura H, Maeda T, Takahashi S, Masumori N, Hasegawa T, et al. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J Clin Oncol. 2013;43(11):1124–31.

    Article  PubMed  Google Scholar 

  18. Pellucchi F, Freschi M, Moschini M, Rocchini L, Maccagnano C, Nazareno S, et al. Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non-muscle-invasive bladder cancer. A step forward or back? BJU Int. 2015;115(2):267–73.

    Article  PubMed  Google Scholar 

  19. Mai KT, Bateman J, Djordjevic B, Flood TA, Belanger EC. Clear cell urothelial carcinoma. Int J Surg Pathol. 2017;25(1):18–25.

    Article  PubMed  Google Scholar 

  20. Donhuijsen K, Schmidt U, Richter HJ, Leder LD. Mucoid cytoplasmic inclusions in urothelial carcinomas. Hum Pathol. 1992;23(8):860–4.

    Article  CAS  PubMed  Google Scholar 

  21. Tavora F, Epstein JI. Urothelial carcinoma with abundant myxoid stroma. Hum Pathol. 2009;40(10):1391–8.

    Article  CAS  PubMed  Google Scholar 

  22. Tosoni I, Wagner U, Sauter G, Egloff M, Knönagel H, Alund G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int. 2000;85(1):48–53.

    Article  CAS  PubMed  Google Scholar 

  23. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol. 2003;169(4):1291–4.

    Article  PubMed  Google Scholar 

  24. Flamm J, Havelec L. Factors affecting survival in primary superficial bladder cancer. Eur Urol. 1990;17(2):113–8.

    Article  CAS  PubMed  Google Scholar 

  25. Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, et al. ICUD-EAU international consultation on bladder cancer 2012: pathology. Eur Urol. 2013;63(1):16–35.

    Article  PubMed  Google Scholar 

  26. van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN, Alkhateeb S, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 2010;106(2):206–11.

    Article  PubMed  Google Scholar 

  27. Compérat E, Egevad L, Lopez-Beltran A, Camparo P, Algaba F, Amin M, et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology. 2013;63(6):756–66.

    Article  PubMed  Google Scholar 

  28. Hwang MJ, Kamat AM, Dinney CP, Czerniak B, Guo CC. Bladder cancer involving smooth muscle of indeterminate type or muscularis mucosae in transurethral biopsy specimens. Am J Clin Pathol. 2020;154(2):208–14.

    Google Scholar 

  29. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242–6.

    Article  PubMed  Google Scholar 

  30. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007;51(1):152–60.

    Article  PubMed  Google Scholar 

  31. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185–90.

    Article  PubMed  Google Scholar 

  32. Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol. 2014;191(2):341–5.

    Article  PubMed  Google Scholar 

  33. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol. 2005;174(6):2134–7.

    Article  PubMed  Google Scholar 

  34. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology. 1995;45(1):47–53.

    Article  CAS  PubMed  Google Scholar 

  35. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer. 1990;66(3):543–8.

    Article  CAS  PubMed  Google Scholar 

  36. Jimenez RE, Keane TE, Hardy HT, Amin MB. pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol. 2000;7(1):13–25.

    Article  CAS  PubMed  Google Scholar 

  37. Rouprêt M, Seisen T, Compérat E, Larré S, Mazerolles C, Gobet F, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol. 2013;189(6):2069–76.

    Article  PubMed  Google Scholar 

  38. Paner GP, Ro JY, Wojcik EM, Venkataraman G, Datta MW, Amin MB. Further characterization of the muscle layers and lamina propria of the urinary bladder by systematic histologic mapping: implications for pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2007;31(9):1420–9.

    Article  PubMed  Google Scholar 

  39. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(10):3182–7.

    Article  CAS  Google Scholar 

  40. Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer. 1999;86(6):1035–43.

    Article  CAS  PubMed  Google Scholar 

  41. Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian A, Mansure JJ, et al. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol. 2013;44(1):95–102.

    Article  PubMed  Google Scholar 

  42. Hu Z, Mudaliar K, Quek ML, Paner GP, Barkan GA. Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence. Ann Diagn Pathol. 2014;18(2):49–52.

    Article  PubMed  Google Scholar 

  43. van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol. 2012;61(2):378–84.

    Article  PubMed  Google Scholar 

  44. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) – 2019 update. Eur Urol. 2019;76(5):639–57.

    Google Scholar 

  45. Fransen van de Putte EE, Behrendt MA, Pigot GL, van der Kwast TH, van Rhijn BW. Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder. Curr Opin Urol. 2015;25(5):427–35.

    Article  PubMed  Google Scholar 

  46. Paner GP, Montironi R, Amin MB. Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances. Adv Anat Pathol. 2017;24(3):113–27.

    Article  PubMed  Google Scholar 

  47. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018;73:560–69.

    Google Scholar 

  48. Grignon DJAAH, Algaba F, Amin MB, Comperat E, Dyrskjot L, Epstein JI, Hansel DE, Knochel R, Lloreta J, Lopez-Beltran A, McKenney JK, Netto GJ, Paner G, Reuter VE, Shen SS, Van der Kwast T. In: Moch H, Humphrey PA, Ulbright TM, Retuer VE, editors. Tumors of the urinary tract. 4th ed. Lyon: IARC Press; 2016.

    Google Scholar 

  49. Ananthanarayanan V, Pan Y, Tretiakova M, Amin MB, Cheng L, Epstein JI, et al. Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists. Am J Surg Pathol. 2014;38(2):167–75.

    Article  PubMed  Google Scholar 

  50. Ro JY, Ayala AG, El-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol. 1987;11(9):668–73.

    Article  CAS  PubMed  Google Scholar 

  51. Miyamoto H, Epstein JI. Transurethral resection specimens of the bladder: outcome of invasive urothelial cancer involving muscle bundles indeterminate between muscularis mucosae and muscularis propria. Urology. 2010;76(3):600–2.

    Article  PubMed  Google Scholar 

  52. Amin MB, Trpkov K, Lopez-Beltran A, Grignon D. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38(8):e20–34.

    Article  PubMed  Google Scholar 

  53. Council L, Hameed O. Differential expression of immunohistochemical markers in bladder smooth muscle and myofibroblasts, and the potential utility of desmin, smoothelin, and vimentin in staging of bladder carcinoma. Mod Pathol. 2009;22(5):639–50.

    Article  PubMed  CAS  Google Scholar 

  54. Paner GP, Shen SS, Lapetino S, Venkataraman G, Barkan GA, Quek ML, et al. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. Am J Surg Pathol. 2009;33(1):91–8.

    Article  PubMed  Google Scholar 

  55. Paner GP, Brown JG, Lapetino S, Nese N, Gupta R, Shen SS, et al. Diagnostic use of antibody to smoothelin in the recognition of muscularis propria in transurethral resection of urinary bladder tumor (TURBT) specimens. Am J Surg Pathol. 2010;34(6):792–9.

    Article  PubMed  Google Scholar 

  56. Miyamoto H, Sharma RB, Illei PB, Epstein JI. Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. Am J Surg Pathol. 2010;34(3):418–22.

    Article  PubMed  Google Scholar 

  57. Esrig D, Freeman JA, Elmajian DA, Stein JP, Chen SC, Groshen S, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996;156(3):1071–6.

    Article  CAS  PubMed  Google Scholar 

  58. Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37(6):726–34.

    Article  PubMed  Google Scholar 

  59. Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol. 1977;118(3):399–403.

    Article  CAS  PubMed  Google Scholar 

  60. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004;171(2 Pt 1):646–51.

    Article  PubMed  Google Scholar 

  61. Moschini M, Soria F, Susani M, Korn S, Briganti A, Roupret M, et al. Impact of the level of urothelial carcinoma involvement of the prostate on survival after radical cystectomy. Bladder Cancer (Amsterdam, Netherlands). 2017;3(3):161–9.

    Article  Google Scholar 

  62. Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol. 2004;171(3):1122–7.

    Article  PubMed  Google Scholar 

  63. Mathieu R, Lucca I, Rouprêt M, Briganti A, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. Nat Rev Urol. 2016;13(8):471–9.

    Article  CAS  PubMed  Google Scholar 

  64. Kim HS, Kim M, Jeong CW, Kwak C, Kim HH, Ku JH. Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol. 2014;32(8):1191–9.

    Article  PubMed  Google Scholar 

  65. Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, et al. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int. 2013;111(3):404–11.

    Article  PubMed  Google Scholar 

  66. Matulay JT, Kamat AM. Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res. 2018;7:F1000 Faculty Rev–1137.

    Google Scholar 

  67. Mari A, Kimura S, Foerster B, Abufaraj M, D’Andrea D, Gust KM, et al. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. Urol Oncol. 2018;36(6):293–305.

    Article  PubMed  Google Scholar 

  68. Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM. Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. Int J Urol. 2015;22(2):163–70.

    Article  PubMed  Google Scholar 

  69. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, et al. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011;108(5):687–92.

    PubMed  Google Scholar 

  70. Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Clinicopathological significance of lymphovascular invasion in urothelial carcinoma. Anal Quant Cytol Histol. 2012;34(4):173–9.

    Google Scholar 

  71. Larsen MP, Steinberg GD, Brendler CB, Epstein JI. Use of Ulex europaeus agglutinin I (UEAI) to distinguish vascular and “pseudovascular” invasion in transitional cell carcinoma of bladder with lamina propria invasion. Mod Pathol. 1990;3(1):83–8.

    CAS  PubMed  Google Scholar 

  72. Guo CC, Czerniak B. Bladder cancer in the genomic era. Arch Pathol Lab Med. 2019;143(6):695–704.

    Article  CAS  PubMed  Google Scholar 

  73. Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage M-L, Krucker C, Chapeaublanc E, et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014;6(244):244ra91.

    Article  PubMed  CAS  Google Scholar 

  74. Marzouka N-A-D, Eriksson P, Rovira C, Liedberg F, Sjödahl G, Höglund M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8(1):3737.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Mo Q, Nikolos F, Chen F, Tramel Z, Lee Y-C, Hayashi K, et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J Natl Cancer Inst. 2018;110(5):448–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–33.

    Article  PubMed  Google Scholar 

  77. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, et al. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur Urol. 2016;70(4):611–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al. Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer. Cell Rep. 2019;27(6):1781–93.e4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016;12:105–17.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Sjodahl G. Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel. Methods Mol Biol (Clifton, NJ). 2018;1655:53–64.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo & Bogdan Czerniak

  2. Department of Pathology and Genomic Medicine, Weill Medical College of Cornell University/Houston Methodist Hospital, Houston, TX, USA

    Jae Y. Ro

Authors
  1. Charles C. Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Y. Ro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bogdan Czerniak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles C. Guo .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Haijun Zhou

  2. Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA

    Charles C. Guo

  3. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

    Jae Y. Ro

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Guo, C.C., Ro, J.Y., Czerniak, B. (2021). Invasive Urothelial Carcinoma with Molecular Types. In: Zhou, H., Guo, C.C., Ro, J.Y. (eds) Urinary Bladder Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-71509-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71509-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71508-3

  • Online ISBN: 978-3-030-71509-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation